Role of histone deacetylase inhibitors in relapsed refractory multiple myeloma: A focus on vorinostat and panobinostat

Pharmacotherapy

Volumn 35, Issue 12, 2015, Pages 1173-1188

  Afifi, Salma ^a   Michael, Angela ^a   Azimi, Mahshid ^a   Rodriguez, Mabel ^a   Lendvai, Nikoletta ^a   Landgren, Ola ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

HDAC; histone deacetylase inhibitors; multiple myeloma; panobinostat; refractory; relapsed; treatment; vorinostat

Indexed keywords

AR 42; BELINOSTAT; BORTEZOMIB; CARFILZOMIB; CASPASE 3; CASPASE 9; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DEXAMETHASONE; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; MELPHALAN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PANOBINOSTAT; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; RICOLINOSTAT; ROMIDEPSIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VORINOSTAT; ANTINEOPLASTIC AGENT; HYDROXAMIC ACID; INDOLE DERIVATIVE;

AGGRESOME; ANEMIA; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL (TOPIC); DIARRHEA; DNA METHYLATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; ENZYME ACTIVITY; EPIGENETICS; FATIGUE; G1 PHASE CELL CYCLE CHECKPOINT; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HISTONE MODIFICATION; HOT FLUSH; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; KIDNEY FAILURE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; UPREGULATION; VOMITING; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL;

EID: 84951060048     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1671     Document Type: Article

References (64)

1. Rajkumar SV, Dimopoulos MA, Palumbo A, et al., International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15 (12): 538-48.
2. Siegel RL, Miller KD, Jemal A,. Cancer Statistics, 2015. CA Cancer J Clin 2015; 65 (1): 5-29.
3. Kyle R, Rajkumar S,. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23 (1): 3-9.
4. Kumar SK, Lee JH, Lahuerta JJ, et al., Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26 (1): 149-57.
5. Esteller M,. Epigenetics in Cancer. N Engl J Med 2008; 358: 1148-59.
6. Smith EM, Boyd K, Davies FE,. The potential role of epigenetic therapy in multiple myeloma. Br J Haematol 2009; 148: 702-13.
7. Grunstein M,. Histone acetylation in chromatin structure and transcription. Nature 1997; 389: 349-52.
8. Hideshima T, Anderson KC,. Histone deacetylase inhbitors in the treatment for multiple myeloma. Int J Hematol 2013; 97: 324-32.
9. Dokumanovic M, Clarke C, Marks PA,. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007; 5 (10): 981-9.
10. Kaufman JL, Fabre C, Lonial S, Richardson PG,. Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy. Clin Lymphoma Myeloma Leuk 2013; 13 (4): 370-6.
11. Ocio EM, San Miguel JF,. The DAC system and associations with multiple myeloma. Invest New Drugs 2010; 28: S28-35.
12. Zain J,. Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma. Hematol Oncol Clin N Am 2012; 26: 671-704.
13. Maiso P, Carvajal-Vergara X, Ocio EM, et al., The histone deacetylase inhibitor LBH589 is a potent anti myeloma agent that overcomes drug resistance. Cancer Res 2006; 66 (11): 5781-9.
14. Urashima M, Teoh G, Chauhan D, et al., Interleukin-6 overcomes p21WAF1 upregulation and GI growth arrest induced by dexamethasone and interferon-γ in multiple myeloma cells. Blood 1997; 90 (1): 279-89.
15. Mitsiades N, Mitsiades CS, Richardson PS, et al., Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055-62.
16. Jourdan M, De Vos J, Mechti N, Klein B,. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. Cell Death Differ 2000; 7: 1244-52.
17. Fandy TE, Shankar S, Ross DD, Sausville D, Srivastava RK,. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005; 7 (7): 646-57.
18. Pei XY, Dai Y, Grant S,. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004; 10: 3839-52.
19. Catley L, Weisberg E, Kizitepe T, et al., Aggresome induction by proteasome inhibitor and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006; 108: 3441-9.
20. Lee A, Iwakoshi N, Anderson K, Glimcher LH,. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 2003; 100: 9946-51.
21. Obeng E, Carlson L, Gutman D, Harrington WJ, Lee KP, Boise LH,. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907-16.
22. Hideshima T, Richardson P, Anderson K,. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther 2011; 10: 2034-42.
23. Patheon, Inc. Zolinza (vorinostat) package insert. Mississauga, Ontario, Canada; 2013.
24. Iwamoto M, Friedman EJ, Sandhu P, Agrawal NGB, Rubin EH, Wagner JA,. Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer Chemother Pharmacol 2013; 72: 493-508.
25. Wong NS, Seah EZH, Wang LZ, et al., Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical information in Asian women with breast cancer. Pharmacogenet Genomics 2011; 21: 760-8.
26. Rubin EH, Agrawal NGB, Friedman EJ, et al., A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancers. Clin Cancer Res 2006; 12 (23): 7039-45.
27. Mitsiades CS, Mitsiades NS, McMullan CJ, et al., Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004; 101 (2): 540-5.
28. Richardson P, Mitsiades C, Colson K, et al., Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008; 49 (3): 502-7.
29. Siegel DS, Richardson P, Dimopoulos M, et al., Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer J 2014; 4: e182.
30. Badros A, Burger AM, Philip S, et al., Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009; 15 (16): 5250-7.
31. Weber DM, Graef T, Hussein M, et al., Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012; 12 (5): 319-24.
32. Voorhees PM, Gasparetto C, Osman K, et al., Results of a phase I study of vorinostat in combination with pegylated liposomal doxorubicin and bortezomib in patients with relapsed/refractory multiple myeloma. [Abstract #1955]. Presented at the 53rd ASH Annual Meeting and Exposition. San Diego, CA, December 10-13, 2011.
33. Vesole DH, Bilotti E, Richter JR, et al., Phase I study of carfilzomib, lenalidomide, vorinostat and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Br J Haematol 2015; 171 (1): 52-9
34. Siegel DS, Dimopoulos MA, Yon SS, et al., Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial. [Abstract #480]. Presented at the 53rd ASH Annual Meeting and Exposition. San Diego, CA, December 10-13, 2011.
35. Dimopoulos M, Siegel DS, Lonial S, et al., Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomized, double-blind study. Lancet Oncol 2013; 14: 1129-40.
36. Munster PN, Rubin EH, Van Belle S, et al., A single supratherapeutic dose of vorinostat does not prolong QTc interval in patients with advanced cancer. Clin Cancer Res 2009; 15 (22): 7077-84.
37. Anne M, Sammartino D, Barginear M, Budman D,. Profile of panobinostat and its potential for treatment in solid tumors: an update. Onco Targets Ther 2013; 6: 1613-24.
38. Novartis Pharmaceuticals Corporation. Farydak (panobinostat). East Hanover, New Jersey; 07936.
39. 14C material in advanced cancer patients. Cancer Chemother Pharmacol 2012; 70: 513-22.
40. Hamberg P, Woo M, Chen L, et al., Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), a orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol 2011; 68: 805-13.
41. Shapiro G, Frank R, Dandamudi U, et al., The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer. Cancer Chemother Pharmacol 2012; 68: 555-62.
42. Giles F, Fischer T, Cortes J, et al., A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006; 12: 4628-35.
43. Sharma S, Beck J, Mita M, et al., A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. Invest New Drugs 2013; 31: 974-85.
44. Prince HM, Bishton MJ, Johnstone RW,. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 2009; 5 (5): 601-12.
45. DeAngelo D, Spencer A, Bhalla K, et al., Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 2013; 27: 1628-36.
46. Wolf J, Siegel D, Goldschmidt H, et al., Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma 2012; 53: 1820-3.
47. San-Miguel J, Richardson P, Gunther A, et al., Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 2013; 31: 3696-703.
48. Richardson P, Schlossman R, Alsina M, et al., PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory patients. Blood 2013; 122: 1223-37.
49. San-Miguel J, Hungria V, Yoon S, et al., Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomized, double-blind phase 3 trial. Lancel Oncol 2014; 15: 1195-206.
50. Berdeja J, Hart L, Mace J, et al., Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica 2015; 100 (5): 670-6.
51. Mateos M, Spencer A, Taylor K, et al., Phase Ib study of oral panobinostat (LBH589) plus lenalidomide plus dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 2010; 25: 8030.
52. Chari A, Cho H, Parekh S, et al., A phase II, single-center, open-label study of oral panobinostat in combination with lenalidomide and weekly dexamethasone in patients with multiple myeloma. [Abstract #3486]. Presented at the 56th ASH Annual Meeting and Exposition. San Francisco, CA, December 6-9, 2014.
53. Offindi M, Polloni C, Cavallo F, et al., Phase II study of melphalan, thalidomide, and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma 2012; 53: 1722-7.
54. Berenson J, Hilger J, Yellin O, et al., A phase I/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Ann Hematol 2014; 93: 88-98.
55. Bishton M, Harrison S, Martin B, et al., deciphering the molecular and biological processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 2012; 117: 3658-68.
56. Niesvizky R, Ely S, Tomer M, et al., Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011; 117: 336-42.
57. Harrison S, Quach H, Link E, Seymour JF, et al., A high rate of durable responses with romidepsin, bortezomib and dexamethasone in relapsed or refractory multiple myeloma. Blood 2011; 118: 6274-83.
58. Steele NL, Plumb JA, Vidal L, et al., A phase 1, pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat (PXD101) in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 804-10.
59. Gimsing P, Hansen M, Knudsen LM, et al., A phase 1 clinical trail of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol 2008; 81: 170-6.
60. NCT00431340. A Phase II study of belinostat in combination with bortezomib in patients with relapsed, refractory multiple myeloma. Available at: http://clinicaltrials.gov/ct2/show/NCT00431340 [accessed 08.18.15].
61. Sullivan D, Shingal S, Chuster M, et al., A phase II study of PXD101 in advanced multiple myeloma. Blood 2006; 108 (1): 00-000. Abstract 3583.
62. Santo L, Hideshima T, Kung A, et al., Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor; ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012; 119: 2579-89.
63. Dimopoulos K, Gimsing P, Gronbaek K,. The role of epigenetics in the biology of multiple myeloma. Blood Cancer J 2014; 4: e207.
64. Zhang S, Suvannasankha A, Crean C, White V, Chen C, Farag SS,. The novel histone deacetylase inhibitor, AR-42, inhibits gp130/stat3 pathways and induces apoptosis and cell cycle arrest in multiple myeloma cells. Int J Cancer 2011; 129: 204-13.